J 2018

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids

CHLAPEK, Petr, Viera SLÁVIKOVÁ, Pavel MAZÁNEK, Jaroslav ŠTĚRBA, Renata VESELSKÁ et. al.

Basic information

Original name

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids

Authors

CHLAPEK, Petr (203 Czech Republic, belonging to the institution), Viera SLÁVIKOVÁ (703 Slovakia, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

International Journal of Molecular Sciences, Basel, Switzerland, MDPI AG, 2018, 1422-0067

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.183

RIV identification code

RIV/00216224:14310/18:00106917

Organization unit

Faculty of Science

UT WoS

000424407200129

Keywords in English

retinoids; cell differentiation; differentiation therapy; mechanisms of resistance

Tags

Tags

International impact, Reviewed
Změněno: 27/1/2021 12:58, Mgr. Tereza Miškechová

Abstract

V originále

In this review, we summarize the most common changes in retinoid metabolism and action that may affect the sensitivity of a tumor cell to treatment with retinoids. The availability of retinoids can be regulated by alterations in retinol metabolism or in retinoid intracellular transport, by degradation of retinoids or by their efflux from the cell. Retinoid effects on gene expression can be regulated via retinoid receptors or via other molecules in the transcriptional complex. Finally, the role of small-molecular-weight inhibitors of altered cell signaling pathways in overcoming the resistance to retinoids is also suggested.

Links

LM2015090, research and development project
Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
NV15-34621A, research and development project
Name: Kandidátní biomarkery rezistence k retinoidům u dětí s vysoce rizikovými neuroblastomy